×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
KRYS – krystal biotech, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
KRYS
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
4/16
06:15 pm
krys
3 Under-the-Radar Healthcare Stocks Worth Adding to Your Watchlist [Globe and Mail, The (Toronto, Canada)]
Medium
Report
3 Under-the-Radar Healthcare Stocks Worth Adding to Your Watchlist [Globe and Mail, The (Toronto, Canada)]
4/16
06:13 pm
krys
3 Under-the-Radar Healthcare Stocks Worth Adding to Your Watchlist [Yahoo! Finance]
Medium
Report
3 Under-the-Radar Healthcare Stocks Worth Adding to Your Watchlist [Yahoo! Finance]
4/10
06:07 pm
krys
Krystal Biotech (KRYS) was upgraded by Weiss Ratings from "hold (c+)" to "buy (b-)".
Medium
Report
Krystal Biotech (KRYS) was upgraded by Weiss Ratings from "hold (c+)" to "buy (b-)".
3/29
05:34 pm
krys
Assessing Krystal Biotech (KRYS) Valuation After Recent Share Price Weakness [Yahoo! Finance]
Low
Report
Assessing Krystal Biotech (KRYS) Valuation After Recent Share Price Weakness [Yahoo! Finance]
3/29
08:27 am
krys
MRNA, SRPT, and KRYS Phase 3 Data Will Shape XBI's 2026 Performance [Yahoo! Finance]
Low
Report
MRNA, SRPT, and KRYS Phase 3 Data Will Shape XBI's 2026 Performance [Yahoo! Finance]
3/27
08:02 am
krys
Krystal Biotech (KRYS) is now covered by Wolfe Research. They set a "peer perform" rating on the stock.
Low
Report
Krystal Biotech (KRYS) is now covered by Wolfe Research. They set a "peer perform" rating on the stock.
3/26
06:13 pm
krys
Krystal Biotech (KRYS) was downgraded by Weiss Ratings from "buy (b-)" to "hold (c+)".
Low
Report
Krystal Biotech (KRYS) was downgraded by Weiss Ratings from "buy (b-)" to "hold (c+)".
3/17
05:33 pm
krys
Updated YJUVEK Label and KB803 Progress Could Be A Game Changer For Krystal Biotech (KRYS) [Yahoo! Finance]
Low
Report
Updated YJUVEK Label and KB803 Progress Could Be A Game Changer For Krystal Biotech (KRYS) [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
4/3
04:35 pm
krys
Form ARS Krystal Biotech, Inc. For: Dec 31
Low
Report
Form ARS Krystal Biotech, Inc. For: Dec 31
4/3
04:33 pm
krys
Form DEFA14A Krystal Biotech, Inc.
Low
Report
Form DEFA14A Krystal Biotech, Inc.
4/3
04:31 pm
krys
Form DEF 14A Krystal Biotech, Inc. For: Apr 03
Low
Report
Form DEF 14A Krystal Biotech, Inc. For: Apr 03
3/27
10:19 am
krys
Form SCHEDULE 13G/A Krystal Biotech, Inc. Filed by: VANGUARD GROUP INC
Low
Report
Form SCHEDULE 13G/A Krystal Biotech, Inc. Filed by: VANGUARD GROUP INC
3/6
06:26 pm
krys
Form 3 Krystal Biotech, Inc. For: Mar 01 Filed by: Goux Laurent Louis Jean
Medium
Report
Form 3 Krystal Biotech, Inc. For: Mar 01 Filed by: Goux Laurent Louis Jean
3/6
06:25 pm
krys
Form 3 Krystal Biotech, Inc. For: Mar 01 Filed by: Thomas John Charles
Medium
Report
Form 3 Krystal Biotech, Inc. For: Mar 01 Filed by: Thomas John Charles
3/6
06:23 pm
krys
Form 4 Krystal Biotech, Inc. For: Mar 04 Filed by: Krishnan Suma
Medium
Report
Form 4 Krystal Biotech, Inc. For: Mar 04 Filed by: Krishnan Suma
3/6
06:22 pm
krys
Form 4 Krystal Biotech, Inc. For: Mar 04 Filed by: Krishnan Krish S
Medium
Report
Form 4 Krystal Biotech, Inc. For: Mar 04 Filed by: Krishnan Krish S
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
6/24
Form 8-K Krystal Biotech, Inc. For: Jun 24
41.3%
3/18 Form 4 Krystal Biotech, Inc. For: Mar 16 Filed by: Krishnan Suma 12.1%
7/1 Krystal Biotech, Inc. Added to the Russell 2000 Index 9.5%
3/10 Krystal Biotech Inc (NASDAQ: KRYS) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $100.00 price target on the stock. 9.1%
6/27 Form 8-K Krystal Biotech, Inc. For: Jun 24 8.1%
11/4 Krystal Biotech Inc (NASDAQ: KRYS) had its "buy" rating re-affirmed by analysts at William Blair. 7.5%
4/13 Form DEF 14A Krystal Biotech, Inc. For: May 29 7.3%
11/21 Form 4 Krystal Biotech, Inc. For: Nov 19 Filed by: Riley Antony A 6.3%
11/27 Krystal Biotech Inc (NASDAQ: KRYS) was upgraded by analysts at BidaskClub from a "buy" rating to a "strong-buy" rating. 5.9%
8/27 Krystal Biotech Announces Attendance at Citi’s 14th Annual Biotech Conference 5.8%
3/18 Form 4 Krystal Biotech, Inc. For: Mar 16 Filed by: Krishnan Suma 12.1%
7/1 Krystal Biotech, Inc. Added to the Russell 2000 Index 9.5%
3/10 Krystal Biotech Inc (NASDAQ: KRYS) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $100.00 price target on the stock. 9.1%
6/27 Form 8-K Krystal Biotech, Inc. For: Jun 24 8.1%
11/4 Krystal Biotech Inc (NASDAQ: KRYS) had its "buy" rating re-affirmed by analysts at William Blair. 7.5%
4/13 Form DEF 14A Krystal Biotech, Inc. For: May 29 7.3%
11/21 Form 4 Krystal Biotech, Inc. For: Nov 19 Filed by: Riley Antony A 6.3%
11/27 Krystal Biotech Inc (NASDAQ: KRYS) was upgraded by analysts at BidaskClub from a "buy" rating to a "strong-buy" rating. 5.9%
8/27 Krystal Biotech Announces Attendance at Citi’s 14th Annual Biotech Conference 5.8%
TOP News Decliners
9/27
Krystal Biotech Announces Granting of its First Foreign Patent and Reinforces its IP Portfolio with a New U.S. Patent
-13.6%
6/14 Krystal Submits Investigational New Drug (IND) Application for KB105, Topical Gene Therapy Candidate for Transglutaminase-1 Deficient Autosomal Recessive Congenital Ichthyosis -11.2%
9/24 Krystal Biotech Inc (NASDAQ: KRYS) is now covered by analysts at Goldman Sachs Group Inc. They set a "neutral" rating on the stock. -11.0%
12/18 Form 4 Krystal Biotech, Inc. For: Dec 16 Filed by: Krishnan Suma -10.8%
2/25 Krystal Biotech Announces Change in Financial Leadership -8.0%
8/2 Krystal Biotech Inc (NASDAQ: KRYS) was downgraded by analysts at ValuEngine from a "strong-buy" rating to a "buy" rating. -7.0%
7/23 Krystal Biotech Inc (NASDAQ: KRYS) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $55.00 price target on the stock. -6.9%
2/18 Form SC 13G Krystal Biotech, Inc. Filed by: ORBIMED ADVISORS LLC -5.3%
6/25 Krystal Biotech Inc (NASDAQ: KRYS) had its price target raised by analysts at Guggenheim from $48.00 to $73.00. They now have a "buy" rating on the stock. -5.2%
9/30 Krystal Biotech Inc (NASDAQ: KRYS) was given a new $81.00 price target on by analysts at Guggenheim. They now have a "buy" rating on the stock. -4.5%
6/14 Krystal Submits Investigational New Drug (IND) Application for KB105, Topical Gene Therapy Candidate for Transglutaminase-1 Deficient Autosomal Recessive Congenital Ichthyosis -11.2%
9/24 Krystal Biotech Inc (NASDAQ: KRYS) is now covered by analysts at Goldman Sachs Group Inc. They set a "neutral" rating on the stock. -11.0%
12/18 Form 4 Krystal Biotech, Inc. For: Dec 16 Filed by: Krishnan Suma -10.8%
2/25 Krystal Biotech Announces Change in Financial Leadership -8.0%
8/2 Krystal Biotech Inc (NASDAQ: KRYS) was downgraded by analysts at ValuEngine from a "strong-buy" rating to a "buy" rating. -7.0%
7/23 Krystal Biotech Inc (NASDAQ: KRYS) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $55.00 price target on the stock. -6.9%
2/18 Form SC 13G Krystal Biotech, Inc. Filed by: ORBIMED ADVISORS LLC -5.3%
6/25 Krystal Biotech Inc (NASDAQ: KRYS) had its price target raised by analysts at Guggenheim from $48.00 to $73.00. They now have a "buy" rating on the stock. -5.2%
9/30 Krystal Biotech Inc (NASDAQ: KRYS) was given a new $81.00 price target on by analysts at Guggenheim. They now have a "buy" rating on the stock. -4.5%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: